Get the Stockscreener App
67.91
1.60%
-1.40
Apogee Therapeutics Inc stock is traded at $67.91, with a volume of 836.44K.
It is down -1.60% in the last 24 hours and down -13.67% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$69.31
Open:
$70.02
24h Volume:
836.44K
Relative Volume:
0.89
Market Cap:
$4.64B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-24.66
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+9.58%
1M Performance:
-13.67%
6M Performance:
+82.55%
1Y Performance:
+88.09%
1-Day Range:
$66.79
$71.18
1-Week Range:
$60.35
$71.18
52-Week Range:
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
67.98 | 4.74B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.40 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.39 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
820.54 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.04 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
345.95 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-07-26 | Initiated | Wolfe Research | Peer Perform |
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
What is Apogee Therapeutics Inc. s 5 year growth outlookDip Buying & Safe Entry Point Identification - mfd.ru
Apogee Therapeutics touts quarterly-to-biannual AD dosing shift, expands asthma ambitions at conference - MarketBeat
Page not foundAirwhon - MarketBeat
APGE: Quarterly dosing, rapid itch relief, and strong safety set up a 2029 launch to challenge market leaders - TradingView
Candriam S.C.A. Invests $5.01 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Can Apogee Therapeutics Inc. sustain earnings growth2025 Year in Review & Capital Efficient Trade Techniques - mfd.ru
Apogee Therapeutics stock hits 52-week high at 62.24 USD By Investing.com - Investing.com South Africa
Apogee Therapeutics stock hits 52-week high at 62.24 USD - Investing.com
Smart Money: Should I set a stop loss on Lichen International LimitedEarnings Growth Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (APGE) Edition - Stock Traders Daily
Portfolio Update: What is Apogee Therapeutics Incs 5 year growth outlook2025 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Apogee Therapeutics CMO sells $361,860 in shares By Investing.com - Investing.com Australia
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therap - GuruFocus
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns By Investing.com - Investing.com Canada
Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns - Investing.com
What drives Apogee Therapeutics Inc.’s stock priceEarnings Overview Summary & Low Risk Entry Point Tips - mfd.ru
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Aug Gainers: Can Apogee Therapeutics Inc stock outperform in a bear marketWeekly Stock Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
Exane Asset Management Invests $2.05 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics, Inc. (APGE) Stock Analysis: Unveiling A 49.24% Upside In Biotech - DirectorsTalk Interviews
Does Apogee Therapeutics Inc. meet Warren Buffett’s criteriaEntry Point & Consistent Return Investment Signals - mfd.ru
(APGE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug Shorts: What are TrueBlue Incs growth leversGap Down & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Promising Biotech Stocks To ResearchJanuary 24th - MarketBeat
Aug Breakouts: Whats the RSI of Adicet Bio Inc stockPrice Action & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million By Investing.com - Investing.com Nigeria
Promising Biotech Stocks Worth WatchingJanuary 23rd - MarketBeat
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares - MarketBeat
Fairmount Healthcare Fund II L.P. sells Apogee (APGE) shares for $133.53 million - Investing.com
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns By Investing.com - Investing.com Nigeria
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns - Investing.com India
RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk - marketscreener.com
Apogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) - Seeking Alpha
Apogee Therapeutics, Inc. (APGE) Stock Analysis: A Biotech Gem with a 27.70% Upside Potential - DirectorsTalk Interviews
Bear Alert: Whats the beta of Apogee Therapeutics Inc stock2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Henderson sells $1.6m in stock By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.6m in stock - Investing.com
Price-Driven Insight from (APGE) for Rule-Based Strategy - Stock Traders Daily
What are Apogee Therapeutics Incs growth leversJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Apogee's Pipeline Momentum Driving Investor Confidence? - RTTNews
Apogee Therapeutics stock hits all-time high at 81.0 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.37%
0.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):